DGX vs GH
Quest Diagnostics and Guardant Health, Inc., both Healthcare
Quest Diagnostics is the larger company at $22B against $17B. Over the past year GH returned +239% against +44% for DGX. Ryufin's sector-relative Smart Score puts GH ahead, 10/10 against 6/10.
| Figure | DGX | GH |
|---|---|---|
| Last close | $245 | $171 |
| Market cap | $22B | $17B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.1 | n/a |
| 1-year return | +44% | +239% |
| 5-year return | +90% | +52% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $2.9B in Q1 2026, net income $252M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
Guardant Health, Inc.
Revenue of $335M in Q2 2026, net income null. Its largest reported line is US, 94% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.